ArticleOncotarget2010
p300- and Myc-mediated regulation of glioblastoma multiforme cell differentiation.
Article in Oncotarget, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Tracing the origins of glioblastoma by investigating the role of gliogenic and related neurogenic genes/signaling pathways in GBM development: a systematic review.World journal of surgical oncology · 2022Pooled it
- The Role of HDAC6 in Glioblastoma Multiforme: A New Avenue to Therapeutic Interventions?Biomedicines · 2024Review
- Downregulation of lncRNACell cycle (Georgetown, Tex.) · 2023Article
- Ion Channel Drugs Suppress Cancer Phenotype in NG108-15 and U87 Cells: Toward Novel Electroceuticals for Glioblastoma.Cancers · 2022Article
- The Protein Arginine Methyltransferases 1 and 5 affect Myc properties in glioblastoma stem cells.Scientific reports · 2019Article
- Article
- Gold quantum dots impair the tumorigenic potential of glioma stem-like cells via β-catenin downregulation in vitro.International journal of nanomedicine · 2019Article
- Vacquinol-1 inducible cell death in glioblastoma multiforme is counter regulated by TRPM7 activity induced by exogenous ATP.Oncotarget · 2017Article
- Extracellular Proton Concentrations Impacts LN229 Glioblastoma Tumor Cell FateFrontiers in oncology · 2017Article
- Deregulated proliferation and differentiation in brain tumors.Cell and tissue research · 2015Review
- Correlation of MicroRNA 132 Up-regulation with an Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy.Translational oncology · 2013Article
- Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling.PLoS computational biology · 2013Article
- Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model.PloS one · 2013Article
- High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells.Oncotarget · 2012Article
- Article
- HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation.Oncogene · 2012Article
- Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas.Cell cycle (Georgetown, Tex.) · 2012Article
- ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma.PloS one · 2012Article
- Mouse models to interrogate the implications of the differentiation status in the ontogeny of gliomas.Oncotarget · 2011Review
- Sumoylation of vimentin354 is associated with PIAS3 inhibition of glioma cell migration.Oncotarget · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Tumorigenic potential of glioblastoma multiforme (GBM) cells is, in part, attributable to their undifferentiated (neural stem cell-like) phenotype. Astrocytic differentiation of GBM cells is associated with transcriptional induction of Glial Fibrillary Acidic Protein (GFAP) and repression of Nestin, whereas the reciprocal transcription program operates in undifferentiated GBM cells. The molecular mechanisms underlying the regulation of these transcription programs remain elusive. Here, we show that the transcriptional co-activator p300 was expressed in GBM tumors and cell lines and acted as an activator of the GFAP gene and a repressor of the Nestin gene. On the other hand, Myc (formerly known as c-Myc overrode these p300 functions by repressing the GFAP gene and inducing the Nestin gene in GBM cells. Moreover, RNAi-mediated inhibition of p300 expression significantly enhanced the invasion potential of GBM cells in vitro. Taken together, these data suggest that dedifferentiated/undifferentiated GBM cells are more invasive than differentiated GBM cells. Because invasion is a major cause of GBM morbidity, differentiation therapy may improve the clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.